BCTX News and Press, BriaCell Therapeutics Corp. From 04/17/23

15 of 18 patients remain alive of those recruited since the study reopened in 2021. Longer than expected patient survival data highlights tolerability and clinical effectiveness of BriaCell’s combination treatment. The Bria-IMT ™ combination regimen...

2023-04-10 14:26:22 ET "Naked Short Selling: What It Is and How It Works." For further details see: SMX Security Matters to probe suspected illegal trading, shares soar

2023-03-30 10:20:27 ET BriaCell Therapeutics ( NASDAQ: BCTX ) is planning a reorganization under which it intends to spin-out certain pre-clinical assets to an unlisted corporation to own the SpinCo Assets (SpinCo). The SpinCo Assets include Bria-TILsRx and PKCδ ...

SpinCo Assets (SpinCo) includes Bria-TILsRx™, and protein kinase C delta (PKCδ) inhibitors for multiple indications including cancer. SpinCo’s goal is to potentially accelerate the development of its assets, and to create value. PHILADELPHIA and VANCOU...

2023-03-24 09:00:16 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group –  Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as ...

PHILADELPHIA and VANCOUVER, British Columbia, March 15, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, has ...

9 of 11 women remain alive from 2021/2022 dosing, highlighting strong survival benefits. Remains well tolerated with no dose limiting toxicities. Primary endpoint in pending pivotal trial will be survival, as agreed by the FDA. 9 additional patients have been s...

Summary BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted novel immuno-therapies to fight breast and prostate cancer. The FDA has agreed on the registration study design which will enroll advanced metastatic breast cancer patients for whom no...

Summary BriaCell Therapeutics aims to create cancer immunotherapy by irradiating and engineering existing cancer cells. Lead candidate Bria-IMT for breast cancer showed good tolerability and efficacy in 46 heavily pretreated patients so far. The potentially pivotal trial is de-riske...

Positive FDA feedback on our pivotal study for lead clinical candidate Bria-IMT™ in combination with a checkpoint inhibitor could greatly accelerate the path to commercialization. Successful completion of the pivotal study could be followed by a Biologics License Application su...